Clinical trial
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes
NCT00106366 · Novo Nordisk A/S, Industry · Completed
Key facts
| NCT number | NCT00106366 |
|---|---|
| Title | Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes |
| Official title | Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes, Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | insulin detemir, insulin glargine, insulin aspart |
| Enrollment | 389 |
| Start date | Mar 1, 2005 |
| Primary completion | Dec 1, 2005 |
| Completion | Dec 1, 2005 |
| First posted | Mar 23, 2005 |
| Last update posted | Jan 31, 2017 |
| Countries | Canada, Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: